Zhou Chengzhi, Deng Haiyi, Yang Yilin, Wang Fei, Lin Xinqing, Liu Ming, Xie Xiaohong, Luan Tao, Zhong Nanshan
State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, China.
KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, Guangdong 511436, China.
Chin Med J (Engl). 2025 Feb 5;138(3):264-277. doi: 10.1097/CM9.0000000000003149. Epub 2024 Oct 11.
With the increasing utilization of cancer therapy, the incidence of lung injury associated with these treatments continues to rise. The recognition of pulmonary toxicity related to cancer therapy has become increasingly critical, for which interstitial lung disease (ILD) is a common cause of mortality. Cancer therapy-related ILD (CT-ILD) can result from a variety of treatments including chemotherapy, targeted therapy, immune checkpoint inhibitors, antibody-drug conjugates, and radiotherapy. CT-ILD may progress rapidly and even be life-threatening; therefore, prompt diagnosis and timely treatment are crucial for effective management. This review aims to provide valuable information on the risk factors associated with CT-ILD; elucidate its underlying mechanisms; discuss its clinical features, imaging, and histological manifestations; and emphasize the clinical-related views of its diagnosis. In addition, this review provides an overview of grading, typing, and staging treatment strategies used for the management of CT-ILD.
随着癌症治疗的应用日益增加，与这些治疗相关的肺损伤发生率持续上升。认识到与癌症治疗相关的肺毒性变得越来越关键，其中间质性肺病（ILD）是常见的死亡原因。癌症治疗相关的ILD（CT-ILD）可由多种治疗引起，包括化疗、靶向治疗、免疫检查点抑制剂、抗体药物偶联物和放疗。CT-ILD可能进展迅速，甚至危及生命；因此，及时诊断和治疗对于有效管理至关重要。本综述旨在提供与CT-ILD相关的危险因素的有价值信息；阐明其潜在机制；讨论其临床特征、影像学和组织学表现；并强调其诊断的临床相关观点。此外，本综述概述了用于管理CT-ILD的分级、分型和分期治疗策略。
